Study objective -To produce a priority list for purchasers to use when purchasing elective care in the speciality of orthopaedics so that efficiency in health care purchasing (that is, maximising the benefit per unit of resource available for the resident population) can be achieved. Design -The study used cost utility analysis in the elective speciality of orthopaedics. The diagnostic groups in the study were chosen on the basis of those conditions that constituted the greatest proportion of the orthopaedic waiting list, and consequently the greatest proportion ofactivity within the speciality. Costs were derived by two methods: the extra contractual referral tariff (ECR) and individual patient based costings. Outcome was assessed before surgery and again approximately six months afterwards. The outcome of the procedures was derived in two ways: Rosser and EuroQol indices. Setting -The study took place at Wrightington hospital, a specialist orthopaedic hospital in north west England. Patients -Prospective assessments were obtained from 99 patients for nine orthopaedics procedures. All the patients were individually interviewed on each occasion. Rosser and EuroQol assessments were completed for each patient by the patient and the patient's consultant before and after surgery.
(J7 Epidemiol Community Health 1996;50: [182] [183] [184] [185] [186] [187] [188] [189] To function effectively in the market, commissioners of health services (purchasers) must be able to make clear and explicit decisions about the goods and services they purchase in order to achieve the "best" possible health care package for their resident population -that is, to maximise efficiency in purchasing. The "new public health" function in purchasing has a role to play in this process which requires prioritisation between competing services or procedures. To do this purchasers need access to information on a range of outcomes, the quality of these outcomes, and about costs -that is, cost benefit information.
The work reported here took place in West Lancashire Health Authority in the north west of England from 1990-92. It develops the application of cost utility analysis to a range of orthopaedic procedures. The published reports on outcome assessment in orthopaedics are clinically dominated and contain very little on the patients' functional and psychological assessment of outcome.`5 The use of health status measurement, and specifically the application of the quality adjusted life year, will extend the purchaser's information set and should facilitate improved decision making.
The quality adjusted life year (QALY) measures the quality and the quantity of life. Hence, the QALY is calculated by multiplying the quality indicator (index value) by the quantity indicator (years of life). Benefit measured by QALY is expressed in terms of a composite numerical index between 0 and 1, where 1 is equivalent to one year in perfect health and 0 is dead or unconscious. The QALY, or index measures in particular, can draw many different aspects of quality of life such as pain and mobility into a common index. Cost utility analysis expresses the benefits and cost of the procedures studied in terms of cost per QALY gained from undertaking each of the procedures. The alternative to an index would be the use of a profile. This can often provide baseline data only, however, that can be highly influenced by external factors. It does not collapse the various dimension of health into a single unit of benefit and faces the decision maker with the dilemma of rating the relative importance of each dimension. This study focuses upon the use of index values.
The study used two index measures to determine health status or benefit after surgery: the Rosser classification of illness states and the EuroQol.
The Rosser classification of illness states6 provides pairwise groupings offour distress and eight disability states experienced by the patient that can be converted into a composite numerical index. The index parameters operate between 0 and 1, where 0 The study population.
The EuroQol8 is a new classification that includes additional aspects of health. There are five dimensions of health each with a 1 (best health) to 3 (worst health) rating. These are mobility, self care, usual activities, pain/discomfort, and anxiety/depression. The five states convert into a composite numerical index between 0 and 1, where 1 represents perfect health and 0 is dead or unconscious. The tariff used was the original one from Frome, Somerset.
Orthopaedic surgery was chosen as the speciality with which to explore prioritisation because it has a set of discrete procedures each with relatively clear indications for their use and each leading to potential benefits which could be assessed after a relatively short time. Elective orthopaedics has notoriously long waiting times9 and is believed to be one of the major elective areas where substantial health gains may be made. Hence we intended to extend both practically and theoretically the work began by Gudex et allo in general surgery.
Method
The study population comprised all patients under the care of each of the participating orthopaedic surgeons at a single speciality orthopaedic hospital between May and August 1991 for one of the nine procedures shown in the figure and detailed in appendix I. The study was explained to the patients in writing and verbally before obtaining their informed consent. The patients were assessed preoperatively and six months postdischarge by which time the full benefits of surgery should have been realised. Patients were sent up to three follow up appointments. Those who failed to attend were sent copies of the assessment forms by post. If these were not returned, up to three attempted telephoned contacts were made.
The nine procedures were those that constituted the greatest proportion of the orthopaedic waiting list, and furthermore the greatest proportion of the activity within the speciality. The patients' conditions were chronic with little change in health status expected without surgical intervention. The procedures undertaken affect quality of life rather than life expectancy. Because the procedures used are well established as technically successful it was not necessary, or indeed ethically acceptable, to undertake a randomised controlled trial. Hence the "before and after" study design.
In addition to assessments of the patients' health states by the researcher (MJ), independent assessments were undertaken by each patient's consultant. The patients completed, unaided, the EuroQol self reported health states8 before and after surgery, these were then converted into a single health status index number using the tariff provided by the York EuroQol team using valuations of health states obtained from a population in Frome, Somerset (personal communication Gudex) . A similar approach was taken to the administration of the Rosser health status classification, although patients did require occasional assistance. In addition, general questions were asked regarding the duration of illness, quality of life over time, comorbidities, and any subsequent complications.
Costs were attached to all the procedures in the analysis. These were calculated by two different approaches: extra contractual referral tariff (ECR) and patient based individually derived costs, the latter undertaken by detailed data extraction from the case notes. The ECR tariff reflects the market price of the good, in this case the average price for a procedure as a proportion of the total budget within orthopaedics. It may be used as a first point of The costing process at Wrightington was sufficiently sophisticated, such that the ECR tariff and patient costs were indeed similar. Henceforth the findings of the study are reported using the patient based costs.
Costs and benefits do not remain constant, and it is the stream of costs and benefits over time that are important for cost utility analysis and cost per QALY calculations (see the report by Williams" on multiple sclerosis). In this analysis factors taken into consideration were as follows: the patients' life span and, where appropriate, length of life of the prosthesis; the probability of complications (derived from the consultants' own data and the published reports; the probability of failure (included in the calculations by percentage that benefit); and the decay point, that is the point in time from which the prosthesis starts to decay, and decay rate ofbenefit over time. The net gain in quality of life is therefore calculated by subtracting the initial health state valuation from the final, multiplied by the years of remaining life and subject to the adjustments factors detailed above (see appendix II). Costs in orthopaedic surgery occur primarily during the hospital inpatient stay, or within the first six months out of patient follow up; hence discounting future costs is largely unnecessary except for the probability of revision surgery. Where appropriate costs were discounted using the recommended treasury rate of 6%.
Sensitivity analyses were performed to test the robustness of the resulting cost utility rankings. These included altering the costs of the prosthesis, the estimates concerning the expected life of the prosthesis, and scenarios where patient outcome reflected the best quality of life improvement from the patients' experiences.
Results Table 1 shows the pre-operative and postoperative completion rates of the quality of life assessments. Ninety nine patient outcome assessments were obtained.
The values and ranges of the patients' and consultants' assessments of the patients' health status before and after surgery are presented in tables 2 and 3. This is calculated for each individual patient using the response to the health status questionnaire and inputing the health valuation tariff value, as described earlier, for both the Rosser and the EuroQol health status assessment questionnaires. These index values are then used throughout to calculate the QALYs per patient per procedure. It should be stressed that as with any range the potential difference is broad, and attainment of a "perfect" health status of 1 is subject to the limitations and sensitivities of the health status assessment measures.
No statistically significant difference was found between either the patient or the consultant preoperative assessments, by either the Rosser or EuroQol measures. A statistically significant difference (p<0001) was found postoperatively for both the Rosser and EuroQol assessments. In both cases, the consultants rated the outcome higher than did the patients. In the overall improvement scores, no statistically significant difference between patient and consultant ratings was found for the Rosser assessments, however, a significant difference was found for the EuroQol assessments.
Breakdown of this difference by operative procedure showed that for spinal surgery, foot surgery, revision hip surgery, Dupuytren's contracture, flexor tenosynovectomy, and carpal tunnel syndrome, there were no statistically significant differences between the consultants' and patients' ratings either preoperatively, postoperatively, or in overall improvement using either a Rosser or EuroQol assessment. In both primary hip replacement and primary knee replacement clinicians rated final outcome markedly higher than patients; with the EuroQol valuations metacarpophalangeal joint replacement was also rated higher by clinicians. In only two instances were improvement statistically significantly different by procedure between patients and consultants -knee replacements and metacaropophalangeal joint replacement assessed by the EuroQol tool. Tables 4 and 5 The costs considered in this study are those that affect the hospital sector. Use of such costs can be justified in as much as it is these costs that purchasers will immediately be interested in when making their purchasing decisions and setting their priorities. A full economic appraisal of a procedure would take a broader view of the costs as they effect society, the economy, and the patient. The broader costs to society are a factor that a decision maker may wish to consider separately.
We have already noted that the patient based costing and prices from the ECR tariffs were negligibly different, thus highlighting the accuracy of Wrightington's accounting process. Costs in other general hospitals may bear no relationship to their quoted ECR tariff prices at the time of the study. General hospitals have the added necessity of firstly breaking down cost to specialty level before they can be disaggregated to procedure level, hence there is greater scope for error and the use of average costs across groups of procedures. Nevertheless, under market forces hospital cost procedures will become increasingly sophisticated and the ECR tariff prices more accurate. Also, use of tariff prices depends on the hospital costs being true costs and not hiding within the tariff elements of cross subsidisation between procedures.
The most important application of index measures is in their ability to provide cost utility ratios and hence rankings for treatments. Consideration of some of the general rankings of procedures within this study raises interesting points. The high cost, high publicity operations such as hip and knee replacements do not necessarily rank highest in the list either in terms of their cost utility ratios or in terms of benefit alone.
The results for upper limb surgery are intriguing. By patient and consultant measures of benefit alone upper limb surgery is ranked towards the bottom of the list (although not always below lower limb surgery). When the cost per QALY rankings are derived, the position changes appreciably especially for carpal tunnel syndrome. This operation produces a very small benefit, but for a long period of time, for very little cost, with negligible chance of recurrence; hence in terms of cost per QALY it is ranked as the number one procedure. That the benefits of upper limb surgery are substantial, for example, by enabling the patient to lead a normal life through such everyday tasks as the use of a knife and fork, is clear from our analysis; they appear to be greater than those accrued from a hip or knee replacement.
Another issue is that of aggregation of benefits and whether large but expensive benefits such as those yielded by hip replacements can justifiably be compared with operations yielding only a small benefit at low cost, for example, carpal tunnel repair. This was a similar problem to that faced by the state of Oregon'8 when choosing between tooth capping and appendectomy.
Priority lists could be expressed in a variety of combinations. These may include cost per QALY bands, diagnostic category, or grouping by major, intermediate, and minor operations (table 7) . Purchasers may find it useful ro rank the groups themselves (as in Oregon'9) into order of priority and then to rank procedures within the groups. Hence, for example, it follows from table 7 that carpal tunnel would be rated at the top of the minor group, but not higher than hip replacement surgery.
Despite their attractions prioritisation tools should be used cautiously and the users of such tools, whether purchasing consortia or the patient themselves, should be aware of the rationale, origins, and the reliability of any cost utility lists. In particular, purchasers should be aware of the potential pitfalls in using "off the peg" priority lists to assist their purchasing decisions. The explicitness in prioritisation is one of the greatest advantages of priority lists. Where revision of a prosthetic replacement occurs as a genuine complication of the host hospital (rather than failure of a joint replaced at another hospital or long term wear and tear), it is assumed that a revision occurs on average approximately five years after the initial joint was replaced.
The final cost figure for each procedure is therefore:
Baseline cost + (cost of revision x probability of revision) discounted by five years (assuming a 6% test discount rate) + (cost of complication x probability of complications) + (cost of readmissions x probabiity of readmissions).
or C=Cb+(Cr x Pr)1/(1 + 006) + (Cc X PC) + (Cra X Pra) Where: C = total cost; Cb = base line cost; Cr= revision cost; Cc = complication cost (excluding hospital admissions); Cra = cost of readmission (excluding readmission as a consequence of revision); P, = probability ofrevision; Pc = probability of complication; Pra =probability of readmission.
Benefits over time Benefit calculations are derived separately for the Rosser QALY and the EuroQol.
The base line benefit is the sum of the final outcome -initial outcome (by procedure)
QL= EQF-XQI
Where: QL= quality of life or benefit in terms of QALYs; QI = initial QALY score; QF = final QALY Score.
QL is presented as an average for each procedure hence the QALY score by procedure (QT) is:
QT = IQLUn
Where n = sample size.
Life expectancy to death (LYD) for each procedure=average years life left until death males x % of males in the sample + average years life left until death in females x % of females in the sample.
TPL=total prosthesis life where: When calculating total benefit in QALY calculations, percentage that benefit would normally need to be built into the QALY calculation, however in this sample the average benefit figure already takes into account the percentage that benefit for each procedure.
